TG Therapeutics Inc.

NASDAQ: TGTX · Real-Time Price · USD
27.98
0.21 (0.76%)
At close: Aug 15, 2025, 3:04 PM

TG Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
329M 233.66M 2.79M 6.69M
Cost of Revenue
38.49M 14.13M 265K 790K
Gross Profit
290.52M 219.53M 2.52M 5.9M
Operating Income
41.93M 20.63M -192.84M -344.77M
Interest Income
n/a n/a n/a n/a
Pretax Income
25.59M 13.06M -198.34M -348.1M
Net Income
23.38M 12.67M -203.83M -355.55M
Selling & General & Admin
154.3M 122.71M 83.23M 152.14M
Research & Development
94.29M 76.19M 112.13M 198.53M
Other Expenses
n/a n/a n/a 2.31M
Operating Expenses
248.59M 198.9M 195.36M 350.67M
Interest Expense
24.03M 12.62M 10.19M 5.64M
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
287.07M 213.03M 195.62M 351.46M
Income Tax Expense
2.21M 390K 5.5M 7.45M
Shares Outstanding (Basic)
145.32M 141.96M 135.41M 132.22M
Shares Outstanding (Diluted)
160.34M 148.51M 135.41M 132.22M
EPS (Basic)
0.16 0.09 -1.51 -2.69
EPS (Diluted)
0.15 0.09 -1.51 -2.69
EBITDA
49.9M 26.1M -187.63M -341.97M
EBIT
49.62M 25.68M -188.14M -342.46M
Depreciation & Amortization
280K 423K 515K 494K